Posted by Michael Wonder on 02 Jun 2020
CDK 4/6 inhibitor market to heat up on insurance benefits
2 June 2020 - Despite such high unmet medical needs, the drug has long been out of reach for patients because the drugs were not entitled to reimbursement as fulvestrant was not reimbursable.
However, the government decided to reimburse fulvestrant in April last year, leading to the reimbursement for Pfizer's Ibrance and Lilly's Verzenio from Monday.
